Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis

NCT07141004 is registered in ClinicalTrials.gov with Johnson & Johnson Private Limited as lead sponsor.

NCT NCT07141004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07141004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis
Lead sponsor
Johnson & Johnson Private Limited
Phase
Phase 4
Overall status
Recruiting
Start date
August 12, 2025
Completion date
September 11, 2027
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic